New Alzheimer’s drug slows cognitive decline by 35%, trial results show
Donanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease
Continue Reading https://www.theguardian.comDonanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease
Continue Reading https://www.theguardian.com
Join the Discussion